SOUTH SAN FRANCISCO, CA--(Marketwired - December 01, 2015) - Neurona Therapeutics Inc., a biotechnology company focused on the transplantation of selected neurons to treat intractable neurological ...
SAN FRANCISCO, June 17, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, today ...
Please provide your email address to receive an email when new articles are posted on . Neurona Therapeutics has announced that a phase 1/2 clinical trial for NRTX-1001, a regenerative neural cell ...
- The oversubscribed private financing round, with primary participation from Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, and Cormorant Asset ...
Almost a year ago to the day, Neurona Therapeutics was cutting staff, citing a difficult funding environment. Fast forward to today, and the company has reeled in a much-needed $120 million. But ...
NRTX-1001 is being assessed for drug-resistant mesial temporal lobe epilepsy Neurona Therapeutics has announced that it has secured $120m in funding to help advance its lead candidate, NRTX-1001, a ...
Belgian pharma company UCB (UCBJY) on Friday announced an agreement to acquire Neurona Therapeutics, a U.S.-based developer of cell therapies for neuronal diseases, for a total consideration of up to ...
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today ...
Hosted on MSN
UCB to purchase Neurona and NRTX-1001 for $1.15bn
UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio. The deal value comprises an ...
SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company advancing regenerative cell therapies for disorders of the nervous ...
- UNILATERAL MTLE: Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy evaluation period (N=9), and 100% median disabling ...
Company Combines Leaders in Fields of Neuroscience and Stem Cell Biology to Develop Cell Therapies With Broad Potential to Treat Neurological Disease SOUTH SAN FRANCISCO, CA--Neurona Therapeutics Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results